Candida albicans malate dehydrogenase Mdh1p has been screened by previous proteome studies as a candidate for a vaccine against candidiasis. In this study, recombinant Mdh1 protein with a His-tag was produced in Escherichia coli and evaluated as an immunogenic protein against candidiasis. Mdh1p was administrated to mice by two methods subcutaneous injection and intranasal administration before challenging them with a lethal dose of C. albicans. After vaccination of Mdh1p, antibody responses were observed. To evaluate the vaccination effect of Mdh1p, survival tests were performed after 35 d. Although all control mice died within 24 d or 25 d, 100% and 80% of mice survived with subcutaneous and intranasal administration, respectively. Therefore, our results indicate that, among C. albicans antigens examined thus far, Mdh1p is currently the most effective antigen for use as a vaccine for C. albicans.
ations, prevention of this fungal infection through vaccination is thought to be an important complementary strategy to pharmacotherapy.
In general, most of the available vaccines are categorized into 3 groups: killed or attenuated pathogenic cells, toxins, and polysaccharide-carrier protein conjugates Fernandez-Arenas et al. 2004 . Additionally, new approaches to vaccine development involve screening specific proteins. For example, a proteome study on hyphal induction an infectious phenotype in C. albicans shows characteristic cell wall protein profiles Heilmann et al., 2011 . Furthermore, we have investigated the virulent protein of C. albicans under the condition containing serum in the medium, by a liquid chromatography/mass spectrometry LC-MS/MS system equipped with a long monolithic capillary column Aoki et al., 2012 . In that study, we found a potential antigen candidate, malate dehydrogenase Candida albicans is an opportunistic fungal pathogen, causing superficial and systemic infections among immunocompromised patients Suido and Miyao, 2008; Brown et al., 2007 . The high mortality rate up to 50% induced by C. albicans in hospitalized patients indicates that this microorganism is one of the most detrimental pathogens to humans Pfaller and Diekema, 2007 . Commonly, pharmacotherapy of candidiasis involves the administration of antifungal drugs, such as caspofungin, micafungin, and amphotericin B. However, approximately half of the treated patients have a poor outcome in spite of antifungal therapy Morschhäuser, 2002; Zaoutis et al., 2005 , and as a result, mutants of Candida with reduced susceptibility to these drugs have emerged Rodloff et al., 2011 . Considering these situ-proteins were separated from insoluble proteins by centrifugation at 27,000 g for 20 min. The supernatant containing soluble proteins was purified by recovering the His6-Mdh1 fusion protein after passage through nickel-chelated agarose Thermo Fisher Scientific columns. The column was equilibrated with 10 ml of B-PER before application of the supernatant. After washing the column with a wash buffer of the B-PER reagent 35 mM Tris, 150 mM NaCl, 10 mM imidazole, 5% v/v glycerol, pH 7.2 , the bound proteins were released with an elution buffer 50 mM Tris, 300 mM NaCl, 200 mM imidazole, 10% v/v glycerol, pH 6.8 . Endotoxins were removed from the eluate by passage through Detoxi-Gel endotoxin-removing columns Pierce, Rockford, IL, USA , resulting in endotoxin levels of 0.1 U/ml, as indicated using Limulus Amebocyte Lysate LAL PYROGENT single-test vials Lonza, Walkersville, MD, USA as described in the manufacturer s protocol.
Female C57BL/6 mice were obtained from Japan SLC, Inc. Shizuoka, Japan . The mice were kept in a specific-pathogen free manner and allowed to drink and eat ad libitum.
Seven-week-old female C57BL/6 mice 5 per group were immunized with 30 g of the recombinant Mdh1p by i.n. delivery or s.c. injection, administered in 20-l volumes containing 1 g of cholera toxin CT Sigma-Aldrich, St. Louis, Mo., USA or 100-l volumes containing Freund s incomplete adjuvant IFA DIFCO Laboratories, Detroit, MI, USA i.n. and s.c., respectively. Seven female C57BL/6 mice of the same age, which received the adjuvant alone mixed with phosphate-buffered saline PBS, pH 7.4 , served as the control group. Mice were immunized at weeks 0, 2, and 4. Blood samples were collected at week 6 from the tail vein, for determination of the titer of serum IgG that binds Mdh1p. The significance of the difference between groups was determined by Student s t-test.
For survival studies, mice were infected with 1.1 10 5 cells of C. albicans, resuspended in 100 l PBS, by tail-vein injection 2 wk after the last immunization. Mice were observed daily for 5 wk after being infected. Animal experimental protocols were approved by the Institutional Animal Care and Use Committee, and animal experiments were conducted according to the institutional ethical guidelines for animal experiments. The outcomes of the challenge with C. albicans were determined using the Kaplan-Meier method. Significant differences between groups were tested using the logrank method.
Indirect enzyme-linked immunosorbent assay ELISA was conducted for antibody analysis of the antisera collected at week 6 i. The plasmid pQE-mdh1, which was used to produce Mdh1p in E. coli, was constructed by first using PCR to amplify the Mdh1p coding sequence using the primers 5 -CATCACCATCACGGATCCTTTTCAAAAGTTGCT ACTAGATCATTTTCCTCTTC-3 and 5 -CTCAGCTAAT TAAGCTT0TTATGGGTTTTGAGCAACAAAGTCAA CACC -3 and genomic DNA of C. albicans strain SC5314 American Type Culture Collection , which was purified as described previously Aoki et al., 2011 . The amplified fragment of the Mdh1p coding sequence was inserted into the pQE30 plasmid QIAGEN, Hilden, Germany that had been digested with BamHI and HindIII, and the resultant plasmid was named pQE-mdh1. pQE-mdh1 was introduced into the E. coli BL21 strain as described previously Hanahan, 1983 for propagation. The nucleotide sequence of the constructed plasmid was confirmed using an ABI PRISM 3130 Genetic Analyzer Applied Biosystems, Foster City, CA, USA .
Mdh1p was produced in the E. coli strain BL21 DE3 as a fusion protein with an N-terminal His6 tag. The cells were inoculated in 14 ml of LB medium, containing 100 g/ml ampicillin, and grown in shake flasks overnight at 37 . Fresh LB medium, containing 100 g/ml ampicillin 120 ml , was inoculated with 6 ml of the overnight cultures, and the cells were grown at 37 until OD 600 = 0.6-1.0
. Gene expression was then i n d u c e d b y t h e a d d i t i o n o f i s o p r o p y l -D -thiogalactoside IPTG;
Wako Pure Chemical, Osaka, Japan to a final concentration of 1 mM Inaoka et al., 1999 . After 3-4 h of cultivation at 37 , the cell cultures were harvested by centrifugation 4,000 g, 20 min, 4 . The cell pellets were subsequently resuspended in 10 ml of bacterial protein extraction reagent B-PER; Thermo Fisher Scientific, IL, USA and shaken gently for 10 min at room temperature 25
. Soluble
We used both s.c. injection and i.n administration to evaluate which delivery of recombinant Mdh1p could induce immunity effectively. The extent to which vaccination with Mdh1p could offer protection against candidiasis was determined by testing the survival after administration of a lethal dose of C. albicans. Administration of Mdh1p with the adjuvant IFA by s.c. administration enhanced titers of IgG bound to Mdh1p Fig. 1a . At 35 d after challenge with a lethal dose of C. albicans, 100% of the mice vaccinated with Mdh1p were alive, while none of the control animals administered the adjuvant only and infected with the same dose of C. albicans survived longer than 24 d after infection Fig. 1b . To date, the effects against systemic candidiasis of a vaccine based on several proteins derived from C. albicans have been examined in other studies in the same manner as in our evaluation. For example, GPI-anchored hyphal cell wall protein Hyr1p Luo et al., 2010 , fructose-bisphosphate aldolase Fba , enolase 1 Eno1p , glyceraldehyde-3-phosphate dehydrogenase Gap1p , and phosphoglycerate kinase Pgk1p Xin and Cutler, 2011 have been evaluated. However, none of those proteins, when administered after infection with C. albicans, resulted in more than 80% survival at 35 d. Therefore and in contrast to other previously tested proteins, Mdh1p is a promising potential vaccine candidate against candidiasis.
As was observed for s.c. injection, i.n. administration of Mdh1p with the adjuvant CT increased titers of the Mdh1p-specific antibody Fig. 2a . The average value of titers of the Mdh1p-specific antibody was 3.7 10 3 , while the value in the case of s.c. injection was 1.0 10 7 Fig. 1a . In addition, the survival test was performed, and approximately 80% as many animals Rochester, NY, USA were coated with 50 l/well of E. coli-expressed recombinant Mdh1p 0.01 g/ l . The plates were blocked with 1% bovine serum albumin BSA dissolved in PBS with 0.05% Tween-20. Serially diluted antisera and horseradish peroxidase HRPconjugated goat anti-mouse IgG 1/4000, Promega, Madison, WI, USA , followed by its substrate, were added to wells. After 20-min incubation at room temperature, the reaction was stopped by addition of 1 M sulfuric acid, and the absorbance was measured at 450 nm OD 450 using a microplate reader Bio-Rad Laboratories Inc., Redmond, WA, USA . The serum IgG antibody titer was defined as the serum dilution that gave an OD 450 value equal to 0.1.
The use of PCR to amplify the Mdh1p-coding sequence, using genomic DNA isolated from C. albicans as a template, yielded a fragment of the expected size, which was cloned into the pQE30 vector that was designed to produce His-tagged recombinant proteins in E. coli. After confirmation that the nucleotide sequence of pQE-mdh1 was correct by comparison with the Candida genome database http://www. candidagenome.org/ , the plasmid was introduced into E. coli BL21, and the recombinant protein was produced in the cytosol and then recovered and purified by passage of the extract through a Ni-chelated column. The recombinant protein was further purified by passage through an endotoxin-removing column. The concentration of endotoxins in the eluate from the Ni-chelated column ranged from 0.06 to 0.125 endotoxin units EU per milliliter. Analysis of Mdh1p by using SDS-PAGE and Western blotting indicated that the anti-His antibody recognized a purified protein data not shown . In conclusion, our findings revealed for the first time that both s.c. and i.n. administration of Mdh1p appeared to induce protective immunity against C. albicans. We have narrowed our focus to a candidate antigen, Mdh1p, screened by two different proteome studies. This approach was thought to lead to finding a high vaccination effect. Convenient tools for further analysis of antigenic protein candidates generated by large-scale screening proteome studies are needed. For example, molecular display technology for microorganism cells such as the arming yeast Shibasaki et al., 2009 Shibasaki et al., , 2010 Tamaru et al., 2006 would be a convenient tool to evaluate the efficacy of their antigenic properties against candidiasis.
